232 related articles for article (PubMed ID: 17137090)
21. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
[TBL] [Abstract][Full Text] [Related]
22. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004.
Harris AH; Hill SR; Chin G; Li JJ; Walkom E
Med Decis Making; 2008; 28(5):713-22. PubMed ID: 18378939
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness and quality-of-life analysis of physician-staffed helicopter emergency medical services.
Ringburg AN; Polinder S; Meulman TJ; Steyerberg EW; van Lieshout EM; Patka P; van Beeck EF; Schipper IB
Br J Surg; 2009 Nov; 96(11):1365-70. PubMed ID: 19847879
[TBL] [Abstract][Full Text] [Related]
24. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
[TBL] [Abstract][Full Text] [Related]
25. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population.
Cowie MR; Marshall D; Drummond M; Ferko N; Maschio M; Ekman M; de Roy L; Heidbuchel H; Verboven Y; Braunschweig F; Linde C; Boriani G
Europace; 2009 Jun; 11(6):716-26. PubMed ID: 19359333
[TBL] [Abstract][Full Text] [Related]
26. The incremental cost effectiveness of in-patient versus out-patient rehabilitation after total hip arthroplasty - results of a pilot investigation.
Krummenauer F; Günther KP; Witzlebf WC
Eur J Med Res; 2008 Jun; 13(6):267-74. PubMed ID: 18558552
[TBL] [Abstract][Full Text] [Related]
27. [Cost-effectiveness: euros per QALY is not enough].
van den Berg M; Hamberg-van Reenen HH; Schoemaker CG
Ned Tijdschr Geneeskd; 2012; 156(5):A3817. PubMed ID: 22296895
[TBL] [Abstract][Full Text] [Related]
28. Effect of health-related quality-of-life instrument and quality-adjusted life year calculation method on the number of life years gained in the critical care setting.
Vainiola T; Roine RP; Pettilä V; Kantola T; Räsänen P; Sintonen H
Value Health; 2011 Dec; 14(8):1130-4. PubMed ID: 22152183
[TBL] [Abstract][Full Text] [Related]
29. Shoulder acute pain in primary health care: is retraining GPs effective? The SAPPHIRE randomized trial: a cost-effectiveness analysis.
McKenna C; Bojke L; Manca A; Adebajo A; Dickson J; Helliwell P; Morton V; Russell I; Torgerson D; Watson J
Rheumatology (Oxford); 2009 May; 48(5):558-63. PubMed ID: 19258378
[TBL] [Abstract][Full Text] [Related]
30. The costs and benefits of bone marrow transplantation.
Beard ME; Inder AB; Allen JR; Hart DN; Heaton DC; Spearing RL
N Z Med J; 1991 Jul; 104(916):303-5. PubMed ID: 1906588
[TBL] [Abstract][Full Text] [Related]
31. Costs and quality of life of multiple sclerosis in Italy.
Kobelt G; Berg J; Lindgren P; Battaglia M; Lucioni C; Uccelli A
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S45-54. PubMed ID: 17310336
[TBL] [Abstract][Full Text] [Related]
32. Cost effectiveness of the determination of autoantibodies against cyclic citrullinated peptide in the early diagnosis of rheumatoid arthritis.
Konnopka A; Conrad K; Baerwald C; König HH
Ann Rheum Dis; 2008 Oct; 67(10):1399-405. PubMed ID: 18192304
[TBL] [Abstract][Full Text] [Related]
33. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
Sorensen SV; Frick KD; Wade A; Simko R; Burge R
Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
[TBL] [Abstract][Full Text] [Related]
34. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
[TBL] [Abstract][Full Text] [Related]
35. Cost effectiveness of community-based physical activity interventions.
Roux L; Pratt M; Tengs TO; Yore MM; Yanagawa TL; Van Den Bos J; Rutt C; Brownson RC; Powell KE; Heath G; Kohl HW; Teutsch S; Cawley J; Lee IM; West L; Buchner DM
Am J Prev Med; 2008 Dec; 35(6):578-88. PubMed ID: 19000846
[TBL] [Abstract][Full Text] [Related]
36. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.
van den Hout WB; Goekoop-Ruiterman YP; Allaart CF; de Vries-Bouwstra JK; Hazes JM; Kerstens PJ; van Zeben D; Hulsmans HM; de Jonge-Bok JM; de Sonnaville PB; Dijkmans BA; Breedveld FC
Arthritis Rheum; 2009 Mar; 61(3):291-9. PubMed ID: 19248130
[TBL] [Abstract][Full Text] [Related]
37. A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness.
Gandjour A; Stock S
Health Policy; 2007 Oct; 83(2-3):257-67. PubMed ID: 17335933
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
Kasteng F; Erlanson M; Hagberg H; Kimby E; Relander T; Lundkvist J
Acta Oncol; 2008; 47(6):1029-36. PubMed ID: 18607857
[TBL] [Abstract][Full Text] [Related]
39. [Cost-utility analysis; uncertainties restrict applicability].
de Neeling JN
Ned Tijdschr Geneeskd; 2004 May; 148(22):1106-10. PubMed ID: 15198066
[TBL] [Abstract][Full Text] [Related]
40. An unadjusted NNT was a moderately good predictor of health benefit.
Chong CA; Tomlinson G; Chodirker L; Figdor N; Uster M; Naglie G; Krahn MD
J Clin Epidemiol; 2006 Mar; 59(3):224-33. PubMed ID: 16488352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
